<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981119</url>
  </required_header>
  <id_info>
    <org_study_id>A2B101-101</org_study_id>
    <nct_id>NCT04981119</nct_id>
  </id_info>
  <brief_title>Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Leukapheresis for CAR T- Cell Manufacturing</brief_title>
  <acronym>BASECAMP-1</acronym>
  <official_title>An Observational Study Obtaining Solid Tumor Tissue From Subjects With Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A2 Biotherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tempus Labs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>A2 Biotherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:&#xD;
&#xD;
      To collect information on how often a solid tumor cancer might lose the Human Leukocyte&#xD;
      Antigen (HLA) by next generation sequencing and perform leukapheresis to collect and store an&#xD;
      eligible participant's own T cells for future use to make CAR T-Cell therapy for their&#xD;
      disease treatment.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      This is a non-interventional, observational study to evaluate subjects with solid tumors with&#xD;
      a high risk of relapse for incurable disease. No interventional therapy will be administered&#xD;
      on this study. Some of the information regarding the participant's tumor analysis may be&#xD;
      beneficial to management of their disease. Participants that meet all criteria may be&#xD;
      enrolled and leukapheresed (blood cells collected). The participant's cells will be processed&#xD;
      and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Human Leukocyte Antigen (HLA) is a protein on the outside of cells that allows the immune&#xD;
      system to recognize it's own cells as normal and leave them alone or respond if infected with&#xD;
      a virus or bacteria, or a tumor cell. HLA might not be expressed normally on cancer cells.&#xD;
      This may be why cancer can grow undetected by the immune system and is referred to as a tumor&#xD;
      escape mechanism. Tumor escape can occur for many reasons, but one reason is Loss of&#xD;
      Heterozygosity (LOH). LOH is the loss of one of the genes that encodes HLA protein. A2&#xD;
      Biotherapeutics, Inc. (A2 Bio) is developing therapies to recognize, target, and kill cancer&#xD;
      cells that do not express HLA normally, and minimize any damage to normal cells that express&#xD;
      normal HLA.&#xD;
&#xD;
      Once participants are identified as having LOH on their tumors, leukapheresis, a procedure to&#xD;
      separate and collect white blood cells will be performed. It is the first required step in&#xD;
      manufacturing CAR T-cell therapy. The collected T cells will be stored for patients that are&#xD;
      likely to benefit from CAR T-cell therapy during their disease care.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Approximately 1000 participants will be screened for part 1 of the study, including HLA&#xD;
      typing, approximately 500 participants will have NGS testing on their tumor samples and be&#xD;
      followed for up to 2 years on the study, and up to 200 participants will be screened for part&#xD;
      2 of the study and enrolled if eligible and leukapheresed and be followed for up to 2 years&#xD;
      on the study.&#xD;
&#xD;
      Participants will be screened (Part 1) for HLA type, and based on results, participants will&#xD;
      have archived tumor tissue tested by next generation sequencing (NGS) and be followed for up&#xD;
      to 2 years. Based on the tumor NGS results, participants will be leukapheresed (Part 2) for&#xD;
      Peripheral Blood Mononuclear Cell (PBMC) collection to store their T cells for a future&#xD;
      interventional study upon relapse.&#xD;
&#xD;
      Each participant will proceed through the following study periods:&#xD;
&#xD;
        -  Screening (Part 1 and 2)&#xD;
&#xD;
        -  Enrollment (Leukapheresis)&#xD;
&#xD;
        -  Post Leukapheresis safety follow-up (Day 7)&#xD;
&#xD;
        -  Two-year long term follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who can enroll in an A2 Biotherapeutics, Inc. CAR T-cell therapy study after undergoing leukapheresis.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Participants will be followed for their status of enrollment on an A2 Biotherapeutics, Inc. interventional study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing.</measure>
    <time_frame>Screening</time_frame>
    <description>Percentage of participants experiencing LOH will be calculated based on NGS results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of enrolled participants who experience an adverse event (AE) related to leukapheresis.</measure>
    <time_frame>7 days</time_frame>
    <description>Adverse events will be collected and monitored for relatedness to leukapheresis during the course of the study.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>CRC</condition>
  <condition>NSCLC</condition>
  <condition>Pancreas Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Leukapheresis procedure performed for collection of PBMCs.</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Next Generation Sequencing (NGS)</intervention_name>
    <description>NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Long Range NGS HLA typing</intervention_name>
    <description>Long range NGS on whole blood to determine germline HLA type.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and archived tumor tissue samples will be obtained for NGS to determine HLA type and&#xD;
      LOH status of tumor tissue. DNA and RNA will be retained for enrolled participants only, if&#xD;
      repeat testing if required. No further genetic testing will be performed on these samples.&#xD;
&#xD;
      Peripheral Blood Mononuclear Cells (PBMCs) will be collected for enrolled subjects, enriched&#xD;
      for T cells and cryopreserved for future manufacturing of an A2 Biotherapeutics, Inc. CAR&#xD;
      T-cell therapy upon participant relapse. No further genetic testing will be performed on this&#xD;
      sample.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or&#xD;
        Pancreatic Cancer (PANC),that is metastatic, unresectable locally advanced, or in the&#xD;
        Investigator's opinion the subject is high risk for incurable relapse within two years,&#xD;
        germline HLA-A*02 heterozygous, and have confirmed somatic LOH.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria&#xD;
&#xD;
        1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell&#xD;
        Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally&#xD;
        advanced, or in the Investigator's opinion the subject is high risk for incurable relapse&#xD;
        within two years.&#xD;
&#xD;
        Part 1: Key Exclusion Criteria&#xD;
&#xD;
          1. History of any of other malignancy in the past 5 years other than non-melanoma skin&#xD;
             carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal&#xD;
             carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.&#xD;
&#xD;
          2. Prior allogeneic stem cell transplant.&#xD;
&#xD;
          3. Prior solid organ transplant.&#xD;
&#xD;
        Part 2 : Key Inclusion Criteria&#xD;
&#xD;
          1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell&#xD;
             Lung Cancer (NSCLC), or Pancreatic Cancer (PANC) that is metastatic, unresectable&#xD;
             locally advanced, or in the Investigator's opinion the subject is high risk for&#xD;
             incurable relapse within two years.&#xD;
&#xD;
          2. Participants are germline HLA-A*02 heterozygous confirmed by HLA typing.&#xD;
&#xD;
          3. Primary tumor tissue showing LOH of HLA-A*02 by NGS testing.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.&#xD;
&#xD;
        Part 2: Key Exclusion Criteria&#xD;
&#xD;
          1. History of any of other malignancy in the past 5 years other than non-melanoma skin&#xD;
             carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal&#xD;
             carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.&#xD;
&#xD;
          2. Prior allogeneic stem cell transplant.&#xD;
&#xD;
          3. Prior solid organ transplant.&#xD;
&#xD;
          4. Participants who have received any cancer therapy on any investigational therapy for&#xD;
             any indication, including but not limited to chemotherapy, small molecules, monoclonal&#xD;
             antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned&#xD;
             leukapheresis or 3 half-lives, whichever is shorter.&#xD;
&#xD;
          5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection&#xD;
             (excluding fungal infections of nail beds) at study enrollment necessitating specific&#xD;
             treatment, or any major episode of infection requiring treatment with Intravenous (IV)&#xD;
             antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of&#xD;
             antibiotic course).&#xD;
&#xD;
          6. Has known active central nervous system metastases. Subjects with previously treated&#xD;
             brain metastases may participate upon medical monitor agreement.&#xD;
&#xD;
          7. In the Investigator's judgement, any other condition or reason the subject would not&#xD;
             complete the required study visits and procedures, and follow up visits, or comply&#xD;
             with the study requirements for participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Go, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>A2 Biotherapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirstin Liechty</last_name>
    <phone>(310)431-9180</phone>
    <email>BASECAMP1@a2bio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sandip Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Hannigan</last_name>
      <email>CHannigan@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>J. Randolph Hecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Garon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Julian Molina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Rosales</last_name>
      <email>kathleen.rosales@nyulangone.edu</email>
    </contact>
    <investigator>
      <last_name>Diane Simeone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Welling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Ross</last_name>
      <phone>713-632-5909</phone>
      <email>kdross@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Scott Kopetz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Pia Morelli, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.a2bio.com</url>
    <description>A2 Bio website</description>
  </link>
  <reference>
    <citation>American Cancer Society. Cancer Facts &amp; Figures 2021. Atlanta: American Cancer Society; 2021</citation>
  </reference>
  <reference>
    <citation>Hamburger AE, DiAndreth B, Cui J, Daris ME, Munguia ML, Deshmukh K, Mock JY, Asuelime GE, Lim ED, Kreke MR, Tokatlian T, Kamb A. Engineered T cells directed at tumors with defined allelic loss. Mol Immunol. 2020 Dec;128:298-310. doi: 10.1016/j.molimm.2020.09.012. Epub 2020 Oct 1.</citation>
    <PMID>33012527</PMID>
  </reference>
  <reference>
    <citation>Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue EH, Paul S, DiNapoli SR, Konig MF, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Vogelstein B, Zhou S, Kinzler KW. Targeting loss of heterozygosity for cancer-specific immunotherapy. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12). pii: e2022410118. doi: 10.1073/pnas.2022410118.</citation>
    <PMID>33731480</PMID>
  </reference>
  <reference>
    <citation>Perera J, Mapes B, Lau D, et al. Detection of human leukocyte antigen class I loss of heterozygosity in solid tumor types by next-generation DNA sequencing. J Immunother Cancer. 2019, 7(Suppl 1):P103</citation>
  </reference>
  <reference>
    <citation>Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.</citation>
    <PMID>20164920</PMID>
  </reference>
  <reference>
    <citation>McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C; TRACERx Consortium. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017 Nov 30;171(6):1259-1271.e11. doi: 10.1016/j.cell.2017.10.001. Epub 2017 Oct 26.</citation>
    <PMID>29107330</PMID>
  </reference>
  <reference>
    <citation>Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23.</citation>
    <PMID>31645765</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T Cell Therapy</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <keyword>Leukapheresis</keyword>
  <keyword>Apheresis</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

